Atlas Trials

A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

Clinical trial NCT02614794 · COMPLETED

Trial details

NCT number
NCT02614794
Sponsor
Seagen Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
HER2 Positive Breast Cancer
Start date
2016-01-28
Primary completion
2019-09-04
Enrollment
612

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.